Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Failed Bioquivalence Studies Should Accompany ANDAs, FDA's Conner Says

Executive Summary

FDA is considering issuing a guidance with instructions for ANDA sponsors on submitting failed bioequivalence studies.

You may also be interested in...



Failed bioequivalence submissions

FDA proposes amending its ANDA in vivo bioequivalence regulations to require submission of data "from all BE studies the applicant conducts on a drug product formulation submitted for approval," instead of only those studies meeting the necessary BE criteria. The amended regs will require "all additional passing and nonpassing BE studies conducted" to be submitted "in either a complete or summary report," HHS' Unified Agenda for 2002 says. The advance notice of proposed rulemaking is due out in February. FDA is concerned that submissions often do not include failed BE studies (1"The Pink Sheet" Oct. 23, 2000, p. 25)...

Failed bioequivalence submissions

FDA proposes amending its ANDA in vivo bioequivalence regulations to require submission of data "from all BE studies the applicant conducts on a drug product formulation submitted for approval," instead of only those studies meeting the necessary BE criteria. The amended regs will require "all additional passing and nonpassing BE studies conducted" to be submitted "in either a complete or summary report," HHS' Unified Agenda for 2002 says. The advance notice of proposed rulemaking is due out in February. FDA is concerned that submissions often do not include failed BE studies (1"The Pink Sheet" Oct. 23, 2000, p. 25)...

SangStat To Sell Transplant Pharmacy To Chain Drug Store By Q1 2001

SangStat expects to sell its specialty mail-order service, The Transplant Pharmacy, to a chain drug store by the end of the first quarter 2001.

UsernamePublicRestriction

Register

PS036771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel